Alan Peter Lewis

This inventor holds 26 USPTO granted patents and 30 published patent applications, plus 3 CIPO patents and 10 EPO patents, primarily in Biopharmaceutical Innovations. Top assignees: Glaxosmithkline Intellectual Property Development Limited, Glaxo Group Limited, Glaxosmithkline LLC. Active years: 1996-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Alan Peter Lewis. Retrieved from https://idiyas.com/inventor/alan-peter-lewis

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 (Patent Applications = 30)

% Patents Active = 65.4

CIPO Patents = 3 (Patent Applications = 6)

EPO Patents = 10 (Patent Applications = 26)

Average Co-Inventor Count = 5.8

ph-index = 4

Forward Citations = 139(Granted Patents)

Location History:

Beckenham, Kent, BR3 3BS, GB (1996)
Stevenage, GB (2010 - 2024)

Company Filing History:

12 out of 242

Glaxosmithkline Intellectual Property Development Limited

4. 1 out of 834,453

Other

patents

Years Active: 1996-2025

Loading Chart...

Areas of Expertise:

Antigen Binding Proteins

Biopharmaceutical Compositions

Antibody Variants

IL-7 Binding Proteins

Neurological Disorders

Recombinant Proteins

CDR Grafted Antibodies

B Cell Maturation Antigen

Humanized Antibodies

Modified Proteins

Binding Agonists

Immunoglobulins

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12466893 - ANTIGEN BINDING PROTEINS (2025-11-11),

2. 12122828 - IL-7 binding proteins and their use in medical therapy (2024-10-22),

3. 11976113 - Biopharmaceutical compositions comprising nucleic acids encoding IL-5 binding proteins (2024-05-07),

4. 11802150 - IL-7 binding proteins and their use in medical therapy (2023-10-31),

5. 11613571 - Biopharmaceutical compositions comprising antibody variants (2023-03-28),

6. 11566347 - Antibody variants (2023-01-31),

7. 11419945 - Antigen binding proteins (2022-08-23),

8. 11203632 - Antibody variants (2021-12-21),

9. 11098312 - Method of producing a recombinant protein (2021-08-24),

10. 11078287 - Binding agonist for treatment of neurological and other disorders (2021-08-03),

11. 10808040 - Modified proteins and peptides (2020-10-20),

12. 10787509 - Biopharmaceutical compositions and related methods (2020-09-29),

13. 10344088 - Antigen binding proteins (2019-07-09),

14. 10280221 - Anti-LAG-3 binding proteins (2019-05-07),

15. 10221234 - Antigen binding proteins (2019-03-05),

Title: Alan Peter Lewis: Innovative Contributions in Biopharmaceuticals

Introduction

Alan Peter Lewis, based in Stevenage, GB, is a prominent inventor with a remarkable portfolio of 24 patents. His work primarily focuses on the development of biopharmaceutical compositions, contributing significantly to medical therapies.

Latest Patents

Among his latest patents are groundbreaking innovations such as IL-7 binding proteins and their use in medical therapy. These patents involve interleukin 7 (IL-7) binding proteins, pharmaceutical compositions, and their applications in treating or preventing various diseases. Moreover, he holds patents related to biopharmaceutical compositions comprising nucleic acids encoding IL-5 binding proteins, aimed at treating diseases mediated by interleukin 5 (IL-5).

Career Highlights

Throughout his career, Alan has made substantial contributions while working with reputable companies like GlaxoSmithKline Intellectual Property Development Limited and Glaxo Group Limited. His innovative mindset and expertise have positioned him as a key player in the biopharmaceutical industry.

Collaborations

Collaboration has been essential to Alan's work, and he has partnered with notable colleagues, including Paul Andrew Hamblin and Tejinder Kaur Bhinder. Together, they have worked on various projects that advance the field of medical therapy.

Conclusion

Alan Peter Lewis exemplifies the innovative spirit within the biopharmaceutical sector. His numerous patents and collaborative efforts highlight his commitment to advancing medical therapies, paving the way for future breakthroughs in the treatment of diseases.

Profile summary based on public USPTO records.